Compare ALT & AAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALT | AAM |
|---|---|---|
| Founded | 1997 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 466.1M |
| IPO Year | N/A | 2024 |
| Metric | ALT | AAM |
|---|---|---|
| Price | $3.61 | $10.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $16.33 | N/A |
| AVG Volume (30 Days) | ★ 4.8M | 61.2K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.33 |
| Revenue | ★ $20,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $32.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $10.08 |
| 52 Week High | $7.83 | $10.79 |
| Indicator | ALT | AAM |
|---|---|---|
| Relative Strength Index (RSI) | 31.14 | 58.50 |
| Support Level | $3.83 | $10.61 |
| Resistance Level | $5.37 | $10.68 |
| Average True Range (ATR) | 0.32 | 0.03 |
| MACD | -0.18 | 0.00 |
| Stochastic Oscillator | 2.39 | 44.44 |
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
AA Mission Acquisition Corp is a blank check company.